Skip to main content
RYTM
NASDAQ Life Sciences

Bivamelagon Phase 2 Win Sets Up Pivotal Trial as Revenue Jumps 80%

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$88.42
Mkt Cap
$5.952B
52W Low
$74.5
52W High
$122.2
52W Position info
19% above low
Off High info
28% below high
Rel. Volume info
9.4× avg
Market data snapshot near publication time

RYTM sits 19% above its 52-week low of $74.5 on elevated volume (9.4× avg).

Summary

Rhythm reported positive Phase 2 results for bivamelagon in acquired hypothalamic obesity and plans to start a pivotal Phase 3 trial by end-2026, with first dosing expected in January. That is the new piece of information here; the Q3 numbers and Japan launch were already out. Q3 revenue came in at $92.1 million, up 80% year over year, with a net loss of $42.4 million, or $0.61 per share, and $320.9 million of cash. The bivamelagon program matters because it is an oral MC4R agonist that could broaden the franchise beyond Imcivree, and the Phase 3 start date gives a concrete milestone. Needham kept its Buy rating but cut its price target to $114 from $130.

At the time of this announcement, RYTM was trading at $88.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

RYTM - Latest Insights

RYTM
Nov 16, 2026, 4:00 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $107.31
Real-time Price: $117.95 info
Change: +$10.64 (+10%) info
Market Cap: $8.18B info
RYTM
Nov 06, 2026, 11:06 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $109.39
Real-time Price: $117.95 info
Change: +$8.56 (+8%) info
Market Cap: $8.18B info
RYTM
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $109.75
Real-time Price: $117.95 info
Change: +$8.20 (+7%) info
Market Cap: $8.18B info
RYTM
Nov 04, 2026, 3:57 PM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $95.21
Real-time Price: $117.95 info
Change: +$22.74 (+24%) info
Market Cap: $8.18B info
RYTM
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $85.70
Real-time Price: $117.95 info
Change: +$32.25 (+38%) info
Market Cap: $8.18B info